BR112022002513A2 - Formas polimórficas de deoxicitidina, composições compreendendo as mesmas e usos - Google Patents

Formas polimórficas de deoxicitidina, composições compreendendo as mesmas e usos

Info

Publication number
BR112022002513A2
BR112022002513A2 BR112022002513A BR112022002513A BR112022002513A2 BR 112022002513 A2 BR112022002513 A2 BR 112022002513A2 BR 112022002513 A BR112022002513 A BR 112022002513A BR 112022002513 A BR112022002513 A BR 112022002513A BR 112022002513 A2 BR112022002513 A2 BR 112022002513A2
Authority
BR
Brazil
Prior art keywords
deoxycytidine
compositions
polymorphic forms
same
methods
Prior art date
Application number
BR112022002513A
Other languages
English (en)
Portuguese (pt)
Inventor
Paul Glidden
Original Assignee
Modis Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modis Therapeutics Inc filed Critical Modis Therapeutics Inc
Publication of BR112022002513A2 publication Critical patent/BR112022002513A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
BR112022002513A 2019-08-19 2020-08-19 Formas polimórficas de deoxicitidina, composições compreendendo as mesmas e usos BR112022002513A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962888893P 2019-08-19 2019-08-19
PCT/US2020/047047 WO2021034962A1 (en) 2019-08-19 2020-08-19 Polymorphic forms of deoxycytidine, compositions comprising the same and uses

Publications (1)

Publication Number Publication Date
BR112022002513A2 true BR112022002513A2 (pt) 2022-05-03

Family

ID=74647126

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022002513A BR112022002513A2 (pt) 2019-08-19 2020-08-19 Formas polimórficas de deoxicitidina, composições compreendendo as mesmas e usos

Country Status (8)

Country Link
US (1) US11649259B2 (cg-RX-API-DMAC7.html)
EP (1) EP4017502A4 (cg-RX-API-DMAC7.html)
JP (2) JP7769603B2 (cg-RX-API-DMAC7.html)
CN (1) CN114929240B (cg-RX-API-DMAC7.html)
AU (1) AU2020334060B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022002513A2 (cg-RX-API-DMAC7.html)
CA (1) CA3150755A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021034962A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022204555A1 (en) * 2021-03-26 2022-09-29 Zogenix Mds, Inc. Aqueous solutions containing purines and pyrimidines and uses thereof
WO2026082601A2 (en) * 2024-10-15 2026-04-23 UCB Biopharma SRL Method of purification

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4898936A (en) * 1984-09-24 1990-02-06 Pcr, Inc. 2-deoxyuridines and riboside precursors
JPS61135597A (ja) * 1984-12-06 1986-06-23 Takeda Chem Ind Ltd シチジンおよびデオキシシチジンの製造法
US4900828A (en) * 1988-05-12 1990-02-13 Hoffmann-Laroche Inc. Intermediate compounds and an improved procedure for the synthesis of 2',3'-dideoxycytidine
JP2002255991A (ja) * 2000-12-27 2002-09-11 Mitsui Chemicals Inc 保護化2’−デオキシシチジン誘導体の製造法
JP2002293791A (ja) * 2001-03-30 2002-10-09 Mitsui Chemicals Inc 保護化2’−デオキシシチジン誘導体の精製法
CN100424091C (zh) * 2002-06-05 2008-10-08 三井化学株式会社 保护化2’-脱氧胞苷类的精制法
EP1551838B1 (en) * 2002-10-16 2006-08-09 Teva Pharmaceutical Industries Ltd. Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
US9669048B2 (en) * 2012-10-25 2017-06-06 Fresenius Kabi Oncology Limited Stable pharmaceutical composition of 5-aza-2′-deoxycitidine
WO2016205671A1 (en) 2015-06-17 2016-12-22 The Trustees Of Columbia University In The City Of New York Deoxynucleoside therapy for diseases caused by unbalanced nucleotide pools including mitochondrial dna depletion syndromes
GB2580963C (en) * 2019-02-01 2025-09-03 Hemispherian As Cancer therapies

Also Published As

Publication number Publication date
JP7769603B2 (ja) 2025-11-13
AU2020334060A1 (en) 2022-03-24
US20210054014A1 (en) 2021-02-25
EP4017502A4 (en) 2023-11-01
CN114929240A (zh) 2022-08-19
JP2025160233A (ja) 2025-10-22
EP4017502A1 (en) 2022-06-29
CA3150755A1 (en) 2021-02-25
CN114929240B (zh) 2024-10-29
AU2020334060B2 (en) 2024-11-14
JP2022544831A (ja) 2022-10-21
US11649259B2 (en) 2023-05-16
WO2021034962A1 (en) 2021-02-25

Similar Documents

Publication Publication Date Title
CO2020016619A2 (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso
ES3063586T3 (en) Novel processes for the production of oligonucleotides
CO2020006900A2 (es) Medios y método para preparar vectores virales y usos de los mismos
DOP2022000172A (es) Compuestos de piperidina urea 4-metilsulfonil-sustituidos para el tratamiento de miocardiopatía dilatada (mcd)
CL2020003007A1 (es) Lactamas biciclicas y metodos de uso de las mismas (divisional solicitud no. 3486-2017)
UY37703A (es) Compuestos heteroarílicos bicíclicos 6-6 fusionados y su uso como inhibidores de lats
MX2019001672A (es) Composiciones de poxvirus quiméricos y usos de las mismas.
CO2018005369A2 (es) Inhibidores triazol de acc y usos de los mismos
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
UY37274A (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
NI201700095A (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
MX2018003058A (es) Formas solidas de derivados de isoquinolinona, proceso de fabricacion, composiciones que las contienen y metodos de uso de las mismas.
MX2018005315A (es) Composiciones y metodos para el tratamiento del cancer.
MX2020007060A (es) Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas.
MX2021005353A (es) Composiciones, metodos y sistemas para el analisis de la corona proteica y usos de los mismos.
UY36733A (es) Nuevos derivados aminoácido, un proceso para su preparación y composiciones farmacéuticas que los contienen
CO2019006687A2 (es) Polimorfos
BR112018010279A2 (pt) novos anticorpos anti-emr2 e métodos de uso
MX2021004925A (es) Variantes de adn-polimerasa modificadas.
BR112018068412A2 (pt) composto, composição farmacêutica, método de tratamento de síndrome mielodisplásica e método para matar uma célula tumoral
CO2019006673A2 (es) Polimorfos
MX2020013713A (es) Formas polimorficas de rad1901-2hcl.
CL2019003213A1 (es) Compuestos plaguicidas bicíclicos.
BR112018012883A2 (pt) novos anticorpos anti-upk1b e métodos de uso
UY40794A (es) Formas cristalinas de (s)-afoxolaner

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: ZOGENIX MDS, INC. (US)

B25A Requested transfer of rights approved

Owner name: ZOGENIX, INC. (US)

B25A Requested transfer of rights approved

Owner name: UCB BIOSCIENCES, INC. (US)

B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]